These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22614325)

  • 1. ALKoma: a cancer subtype with a shared target.
    Mano H
    Cancer Discov; 2012 Jun; 2(6):495-502. PubMed ID: 22614325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
    Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H;
    N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
    Roskoski R
    Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA; Velez M; Raez LE; Santos ES
    Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.
    Berghoff AS; Birner P; Streubel B; Kenner L; Preusser M
    APMIS; 2014 Sep; 122(9):867-72. PubMed ID: 24750504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
    Li R; Morris SW
    Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R
    Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 15. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.
    Tothova Z; Wagner AJ
    Curr Opin Oncol; 2012 Jul; 24(4):409-13. PubMed ID: 22664824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
    Schoppmann SF; Streubel B; Birner P
    Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM; Bepler G
    Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.
    Zhang G; Scarborough H; Kim J; Rozhok AI; Chen YA; Zhang X; Song L; Bai Y; Fang B; Liu RZ; Koomen J; Tan AC; Degregori J; Haura EB
    Sci Signal; 2016 Oct; 9(450):rs12. PubMed ID: 27811184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
    Heuckmann JM; Hölzel M; Sos ML; Heynck S; Balke-Want H; Koker M; Peifer M; Weiss J; Lovly CM; Grütter C; Rauh D; Pao W; Thomas RK
    Clin Cancer Res; 2011 Dec; 17(23):7394-401. PubMed ID: 21948233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.